^
Association details:
| Biomarker: | BCR-ABL1 fusion |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) + SBI-756 (AKT inhibitor, mTORC1 inhibitor, NF-κB inhibitor, eIF4G1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting eIF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition
Published date:
11/04/2021
Excerpt:
SBI-756, a small molecule inhibitor of eIF4F assembly, sensitizes human Ph+ and Ph-like B-ALL cells to dasatinib cytotoxicity without affecting survival of T lymphocytes or natural killer cells. These findings support the further evaluation of eIF4F-targeted molecules in combination therapies with TKIs in B-ALL and other blood cancers.
DOI:
10.1038/s41598-021-00950-y
